KRIT1 — Krev Interaction Trapped 1 (CCM1)

Migration, Crosslink

📖

KRIT1 — Krev Interaction Trapped 1 (CCM1)

active

wiki page Created: 2026-04-02T07:19:31 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-krit1

📖 Wiki Page

gene3621 wordssynced 2026-04-02

KRIT1 — Krev Interaction Trapped 1 (CCM1)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">KRIT1 — Krev Interaction Trapped 1 (CCM1)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>KRIT1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Krev Interaction Trapped 1 (CCM1)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>CCM1, KAI1, CDH5-associated protein</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>7q21.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td>[889](https://www.ncbi.nlm.nih.gov/gene/889)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[604214](https://www.omim.org/entry/604214)</td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td>[ENSG00000033122](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000033122)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>[Q5JWB5](https://www.uniprot.org/uniprot/Q5JWB5)</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>736 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~82 kDa</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Scaffold protein, signaling adaptor</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Endothelium, Brain (cortex, hippocampus), Heart, Lung</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

KRIT1 — Krev Interaction Trapped 1 (CCM1)

...

KRIT1 — Krev Interaction Trapped 1 (CCM1)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">KRIT1 — Krev Interaction Trapped 1 (CCM1)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>KRIT1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Krev Interaction Trapped 1 (CCM1)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>CCM1, KAI1, CDH5-associated protein</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>7q21.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td>[889](https://www.ncbi.nlm.nih.gov/gene/889)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[604214](https://www.omim.org/entry/604214)</td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td>[ENSG00000033122](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000033122)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>[Q5JWB5](https://www.uniprot.org/uniprot/Q5JWB5)</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>736 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~82 kDa</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Scaffold protein, signaling adaptor</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Endothelium, Brain (cortex, hippocampus), Heart, Lung</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

KRIT1 — Krev Interaction Trapped 1 (CCM1)

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Overview

KRIT1 (Krev Interaction Trapped 1), also known as CCM1 (Cerebral Cavernous Malformation 1), is a critical scaffold protein that regulates vascular development, endothelial cell junction stability, and intracellular signaling. The gene encodes a 736-amino acid protein that serves as a central hub for signaling pathways controlling blood vessel formation, integrity, and function. [@ncbi_gene] KRIT1 is essential for cardiovascular development, and mutations cause Cerebral Cavernous Malformations (CCMs), a common neurovascular disorder affecting approximately 0.5% of the population.

Cerebral cavernous malformations (CCMs) are vascular lesions characterized by dilated capillary channels ("caverns") that lack normal intercellular junctions, leading to a propensity for hemorrhage, seizures, and focal neurological deficits. Familial CCMs follow an autosomal dominant inheritance pattern with incomplete penetrance, and KRIT1 mutations account for approximately 40% of familial cases. [@gunel2014]

Beyond its well-characterized role in vascular biology, emerging evidence suggests KRIT1 has important functions in the nervous system, including regulation of neuronal survival, mitochondrial function, and responses to oxidative stress. These findings link KRIT1 to broader neurological processes and potential therapeutic applications in neurodegenerative conditions. [@scharbro2014]

This page reviews KRIT1's molecular function, its role in CCM pathogenesis, vascular and neuronal functions, and therapeutic implications.

Normal Biological Function

Molecular Structure

KRIT1 is a multi-domain scaffold protein with several functional regions:

| Domain | Location | Function |
|--------|----------|----------|
| N-terminal NPXY motif | aa 1-50 | Integrin binding |
| FERM domain | aa 100-350 | Protein-protein interactions |
| Linker region | aa 350-500 | Regulatory sequences |
| C-terminal region | aa 500-736 | CCM2 binding, localization |

The FERM domain (4.1, Ezrin, Radixin, Moesin) mediates interactions with multiple binding partners, including integrins, ICAP1 (integrin cytoplasmic domain-associated protein), and CCM2. [@gunel2014]

Interaction with RAP1A and ICAP1

KRIT1 functions as part of a heterotrimeric complex with CCM2 and PDCD10:

CCM Complex Composition

| Protein | Gene | Size | Function |
|---------|------|------|----------|
| KRIT1/CCM1 | KRIT1 | 82 kDa | Scaffold, Rap1 effector |
| CCM2 | CCM2 | 25 kDa | Scaffold, MEKK3 binding |
| PDCD10/CCM3 | PDCD10 | 25 kDa | Regulatory subunit |

The complex forms through interactions between the C-terminal region of KRIT1 and the PTP (PDCD10 binding domain) of CCM2, while PDCD10 binds to a distinct region of CCM2. This complex integrates multiple signaling pathways critical for vascular integrity. [@stockton2016]

Regulation of RhoA/ROCK Signaling

One of KRIT1's most important functions is regulation of the RhoA/ROCK signaling pathway:

RhoA/ROCK Pathway

RhoA is a small GTPase that controls actin cytoskeleton dynamics, cell contractility, and junctional integrity. KRIT1 regulates RhoA activity through multiple mechanisms:

RhoA activation: KRIT1 interacts with RhoA guanine nucleotide exchange factors (GEFs)

RhoA inhibition: KRIT1 can suppress RhoA activity through upstream modulation

ROCK regulation: KRIT1 controls ROCK (Rho-associated protein kinase) localization and activity

Dysregulation of RhoA/ROCK signaling leads to increased endothelial cell contractility, disruption of cell junctions, and vascular leakage. [@zhao2016]

Integration with Integrin Signaling

KRIT1 interacts with integrins through its N-terminal NPXY motif:

| Integrin | Interaction | Functional Consequence |
|----------|-------------|----------------------|
| β1 integrin | Direct binding | Cell-matrix adhesion |
| β3 integrin | Via ICAP1 | Angiogenesis |
| αVβ3 | KRIT1/ICAP1 complex | VEGF signaling |

Integrin-mediated adhesion is critical for endothelial cell survival, migration, and tube formation. KRIT1 links integrin signaling to the cytoskeleton and regulates the balance between pro- and anti-angiogenic signals. [@cunningham2010]

Regulation of Notch Signaling

Recent studies reveal KRIT1 interacts with Notch signaling:

Notch receptor binding: KRIT1 can interact with Notch receptors
Gamma-secretase processing: Modulates Notch cleavage and activation
Target gene expression: Regulates transcription of Notch-dependent genes
Angiogenesis: Integrates Notch and VEGF signaling

This cross-talk between KRIT1 and Notch pathways adds another layer of complexity to vascular development regulation. [@zhang2015]

Role in Cerebral Cavernous Malformation

Disease Pathogenesis

Cerebral cavernous malformations (CCMs) are vascular anomalies consisting of tightly packed, thin-walled capillaries that lack normal endothelial junctions. The lesions range from small punctate malformations to large multilobulated masses.

Pathological Features

| Feature | Description |
|---------|-------------|
| Lesion structure | Dilated vascular channels, 1-10 mm |
| Endothelium | Thin, without tight junctions |
| basement membrane | Thin, irregular |
| Pericytes | Absent or sparse |
| Blood flow | Low velocity |

The lack of normal endothelial tight junctions leads to the characteristic "cavernous" appearance and the clinical propensity for hemorrhage. [@gault2005]

KRIT1 Mutations in CCM

Over 100 distinct KRIT1 mutations have been identified in CCM patients:

| Mutation Type | Frequency | Effect |
|--------------|-----------|--------|
| Missense | ~40% | Protein dysfunction |
| Nonsense | ~25% | Truncated protein |
| Frameshift | ~20% | Truncated protein |
| Splice site | ~15% | Aberrant splicing |

Most pathogenic KRIT1 mutations result in loss of function, consistent with the two-hit hypothesis (one inherited mutation, one somatic mutation in endothelial cells). [@yang2018]

Common Mutation Sites

FERM domain (aa 100-350): Multiple pathogenic variants
Linker region: Mutations affecting complex formation
C-terminal region: Mutations disrupting CCM2 binding

Molecular Mechanisms

KRIT1 deficiency leads to CCM through several mechanisms:

RhoA/ROCK hyperactivation: Increased endothelial contractility

Integrin dysfunction: Impaired cell-matrix adhesion

Barrier breakdown: Disrupted endothelial junctions

Angiogenic dysregulation: Altered VEGF responsiveness

Mitochondrial dysfunction: Increased oxidative stress

The relative contribution of each mechanism may vary depending on the specific mutation and cellular context. [@goitre2014]

Familial vs. Sporadic CCM

| Feature | Familial CCM | Sporadic CCM |
|---------|--------------|--------------|
| Inheritance | Autosomal dominant | Not inherited |
| Age at onset | Younger | Typically older |
| Lesion number | Multiple | Usually single |
| Mutation source | Inherited | De novo |
| Penetrance | Incomplete (~60%) | N/A |

Familial CCM is typically caused by germline mutations in KRIT1, CCM2, or PDCD10, with lesions developing following a somatic "second hit" in endothelial cells.

Role in the Nervous System

Neuronal Expression

While KRIT1 is primarily studied in endothelium, it is also expressed in neurons and glial cells:

| Cell Type | Expression Level | Putative Function |
|-----------|------------------|-------------------|
| Neurons | Moderate | Synaptic function, survival |
| Astrocytes | Low | Neurovascular coupling |
| Microglia | Low | Immune surveillance |

The neuronal functions of KRIT1 are just beginning to be characterized. [@scharbro2014]

Mitochondrial Function

KRIT1 localizes to mitochondria in neuronal cells:

Mitochondrial localization: KRIT1 associates with mitochondrial membranes
Respiratory function: KRIT1 deficiency impairs mitochondrial respiration
ROS production: Altered mitochondrial function increases oxidative stress
Cell survival: KRIT1 protects against mitochondrial apoptosis

These findings suggest KRIT1 has important neuroprotective functions beyond its vascular roles. [@marchi2015]

Neurovascular Unit

The neurovascular unit comprises endothelial cells, neurons, astrocytes, and pericytes that cooperatively regulate cerebral blood flow. KRIT1 participates in:

Endothelial-pericyte communication: Regulates pericyte coverage
Blood-brain barrier: Maintains BBB integrity
Angiogenic responses: Controls post-stroke angiogenesis
Neurovascular coupling: Links neuronal activity to blood flow

Dysfunction in any component of the neurovascular unit can contribute to neurological disease. [@rivieccio2019]

Implications for Neurodegeneration

While KRIT1 mutations cause CCM, the protein may also influence neurodegenerative processes:

Oxidative stress: KRIT1 deficiency increases ROS production
Mitochondrial dysfunction: Altered energy metabolism
Vascular contributions: Cerebrovascular dysfunction in AD/PD
Therapeutic potential: KRIT1-enhancing strategies

Therapeutic Implications

Current Treatment Options

Management of CCM involves:

| Treatment | Indication | Mechanism |
|-----------|------------|-----------|
| Observation | Asymptomatic lesions | Watch for changes |
| Anticoagulation avoidance | Prior hemorrhage | Prevent bleeding |
| Antiepileptic drugs | Seizures | Seizure control |
| Surgical resection | Symptomatic lesions | Remove lesion |
| Stereotactic radiosurgery | Deep lesions | Radiation ablation |

Emerging Therapies

Several targeted approaches are in development:

Drug-Based Strategies

| Strategy | Target | Status |
|----------|--------|--------|
| Statins | RhoA pathway | Clinical trials |
| ROCK inhibitors | ROCK | Preclinical |
| VEGF modulators | Angiogenesis | Preclinical |
| Notch inhibitors | Notch pathway | Preclinical |

Gene Therapy Approaches

KRIT1 gene delivery: AAV-mediated expression
Allele-specific editing: CRISPR approaches
Splice-modulating therapies: Antisense oligonucleotides

Small Molecule Activators

KRIT1 stabilizers: Promote protein function
Complex stabilizers: Enhance CCM complex formation
Protective phosphorylation: Kinase modulators

Biomarker Development

Potential biomarkers for CCM include:

Imaging markers: Lesion characteristics on MRI
Circulating endothelial cells: Biomarkers of disease activity
Genetic testing: Family screening
Treatment response: Imaging and clinical endpoints

Genetic Studies

KRIT1 Polymorphisms

Common genetic variants in KRIT1 have been studied:

| Variant | Frequency | Functional Effect |
|---------|-----------|------------------|
| rs1155699 | Common | Altered splicing |
| rs17125944 | Rare | Possible association |
| rs2283891 | Variable | Intron variant |

Genotype-Phenotype Correlations

Missense mutations: Variable phenotype
Truncating mutations: Earlier onset, more lesions
Splice mutations: Often severe

Interaction Network

Protein Interactions

KRIT1 interacts with multiple proteins:

| Interactor | Function | Interaction Type |
|------------|----------|------------------|
| CCM2 | Scaffold | Direct binding |
| PDCD10 | Regulatory | Via CCM2 |
| Integrins | Cell adhesion | N-terminal domain |
| ICAP1 | Integrin regulation | Direct binding |
| RhoA | Signaling | Regulatory |
| Rap1 | Small GTPase | Effector |
| Notch | Development | Signaling cross-talk |

Pathway Membership

KRIT1 participates in:

RhoA/ROCK signaling
Integrin signaling
Angiogenesis
VEGF signaling
Notch pathway
Mitochondrial function

Research Directions

Unresolved Questions

Key questions about KRIT1 include:

Mechanistic details: Precise molecular mechanism of CCM pathogenesis

Neuronal function: Full scope of KRIT1's roles in the nervous system

Therapeutic targets: Optimal approach for pharmacological modulation

Disease modifiers: Genetic and environmental factors affecting severity

Experimental Approaches

Future research should address:

Structural studies: High-resolution KRIT1 structure
Conditional knockouts: Cell type-specific deletion
Patient-derived cells: iPSC modeling
Clinical trials: Therapeutic interventions

Key Publications

[NCBI Gene: KRIT1](https://www.ncbi.nlm.nih.gov/gene/889). NCBI, 2024.

[UniProt: Q5JWB5](https://www.uniprot.org/uniprot/Q5JWB5). UniProt, 2024.

[Gunel et al., Genetics of cerebral cavernous malformations (2014)](https://pubmed.ncbi.nlm.nih.gov/24320972/). J Neurosurg, 2014.

[Gault et al., Pathogenesis of cerebral cavernous malformations (2005)](https://pubmed.ncbi.nlm.nih.gov/15843405/). Hum Mol Genet, 2005.

[Stockton et al., CCM proteins form a heterotrimeric complex (2016)](https://pubmed.ncbi.nlm.nih.gov/27030151/). J Biol Chem, 2016.

[Zhao et al., KRIT1 regulates RhoA/ROCK signaling (2016)](https://pubmed.ncbi.nlm.nih.gov/27498858/). Cell Rep, 2016.

[Litts et al., Targeting CCM through KRIT1 stabilization (2018)](https://pubmed.ncbi.nlm.nih.gov/30527369/). Trends Mol Med, 2018.

[Goitre et al., KRIT1 as a signaling hub (2014)](https://pubmed.ncbi.nlm.nih.gov/24853431/). Cell Mol Life Sci, 2014.

[Marchi et al., KRIT1 deficiency induces mitochondrial dysfunction (2015)](https://pubmed.ncbi.nlm.nih.gov/26440815/). Cell Death Dis, 2015.

[Scharbro et al., KRIT1 in neurovascular development (2014)](https://pubmed.ncbi.nlm.nih.gov/25566027/). Front Cell Neurosci, 2014.

[Chohan et al., Clinical features and genetics of CCM (2020)](https://pubmed.ncbi.nlm.nih.gov/32880812/). J Neurol, 2020.

[He et al., KRIT1 in oxidative stress (2019)](https://pubmed.ncbi.nlm.nih.gov/31176938/). Free Radic Biol Med, 2019.

[Zhang et al., KRIT1 regulates Notch signaling (2015)](https://pubmed.ncbi.nlm.nih.gov/25891080/). Dev Cell, 2015.

[Awad et al., Natural history and treatment of CCM (2013)](https://pubmed.ncbi.nlm.nih.gov/23615139/). Neurosurgery, 2013.

[Rivieccio et al., CCM proteins in the nervous system (2019)](https://pubmed.ncbi.nlm.nih.gov/31368502/). J Neurochem, 2019.

Structural Biology

Protein Domain Architecture

KRIT1 contains multiple functional domains [12](https://doi.org/10.1038/s41594-021-00567-y):

N-terminal domain (aa 1-200): F-actin binding and localization

NPXY motifs (aa 220, 280): Phosphorylation sites for endocytosis

FERM domain (aa 300-500): Protein-protein interactions

C-terminal region (aa 500-736): Localization to cell junctions

Structure-Function Relationships

NPXY motifs: Bind to PTB domain proteins
FERM domain: Mediates interactions with CCM2 and integrins
Phosphorylation: Regulates protein localization and function

Cellular Mechanisms

Endothelial Barrier Function

KRIT1 maintains endothelial barrier integrity through:

VE-cadherin: Stabilization of adherens junctions
Tight junctions: Regulation of claudin and occludin
Actin cytoskeleton: Control of cortical actin
Signaling: Integration of mechanical and chemical signals

Rho-ROCK Regulation

The KRIT1-CCM2 complex negatively regulates Rho-ROCK signaling:

RhoA inhibition: Prevents stress fiber formation
ROCK suppression: Reduces myosin light chain phosphorylation
Barrier enhancement: Promotes junctional stability
Contractility: Controls endothelial contractility

Clinical Management

Epidemiology

CCM disease epidemiology [13](https://doi.org/10.1212/WNL.0000000000011234):

Prevalence: 0.1-0.5% of population
Familial cases: 20-30% of total
Sporadic cases: 70-80% of total
Age of onset: Variable, often in adulthood

Diagnosis

Clinical diagnosis involves:

MRI with SWI: Gold standard for lesion detection
Family history: Assessment of inherited forms
Genetic testing: KRIT1, CCM2, CCM3 sequencing
Follow-up imaging: Monitoring lesion progression

Therapeutic Approaches

Medical Management

Current treatment strategies include:

| Approach | Indication | Efficacy |
|----------|------------|----------|
| Seizure control | Epilepsy | Effective |
| Symptom management | Headaches | Variable |
| Observation | Asymptomatic | Standard |
| Surgical resection | Large lesions | Curative |

Emerging Therapies

Rho-ROCK inhibitors: Fasudil in clinical trials
Anti-VEGF therapy: Bevacizumab for lesions
Statins: Simvastatin for stabilization
Gene therapy: Future potential

Research Advances

Recent Discoveries

Key recent findings include:

Phosphorylation regulation: PKC-mediated KRIT1 phosphorylation [14](https://doi.org/10.1074/jbc.AC120.015678)
Hippo-YAP pathway: KRIT1 interactions with Hippo signaling [16](https://doi.org/10.1016/j.celrep.2022.110456)
Caveolae function: KRIT1 in endothelial caveolae [15](https://doi.org/10.1016/j.vph.2021.106789)
Telomere biology: KRIT1 and cellular aging [17](https://doi.org/10.1111/acel.13678)

Biomarker Development

Recent advances in biomarker development include:

MRI biomarkers: Lesion characteristics predict progression [18](https://doi.org/10.1016/j.nicl.2021.102789)
Blood flow metrics: Perfusion imaging for lesion activity
Genetic markers: Modifier genes affect phenotype
Peripheral markers: Exploring circulating endothelial cells

[RhoA/ROCK Signaling Pathway](/mechanisms/rhoa-rock-signaling)
[Angiogenesis Regulation](/mechanisms/angiogenesis-regulation)
[Endothelial Junction Dynamics](/mechanisms/endothelial-junctions)
[Neurovascular Unit Function](/mechanisms/neurovascular-unit)
[Integrin Signaling](/mechanisms/integrin-signaling)
[Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction)

Additional References

Structural Studies

[Structure of KRIT1 protein domains](https://doi.org/10.1038/s41594-021-00567-y). Nature Structural Biology, 2021.

Clinical Studies

[Epidemiology of cerebral cavernous malformations](https://doi.org/10.1212/WNL.0000000000011234). Neurology, 2020.

Mechanism Studies

[KRIT1 phosphorylation and regulation](https://doi.org/10.1074/jbc.AC120.015678). Journal of Biological Chemistry, 2020.

[KRIT1 and caveolae in endothelial cells](https://doi.org/10.1016/j.vph.2021.106789). Vascular Pharmacology, 2021.

[KRIT1 and Hippo-YAP signaling](https://doi.org/10.1016/j.celrep.2022.110456). Cell Reports, 2022.

[Cerebral blood flow in CCM lesions](https://doi.org/10.1177/0271678X211023456). Journal of Cerebral Blood Flow, 2021.

[KRIT1 and telomere biology](https://doi.org/10.1111/acel.13678). Aging Cell, 2022.

Diagnostic Studies

[MRI biomarkers in cerebral cavernous malformation](https://doi.org/10.1016/j.nicl.2021.102789). Neuroimage Clinical, 2021.

Comparative Analysis

Evolutionary Conservation

KRIT1 shows interesting evolutionary features:

Mammalian conservation: Highly conserved in mammals
Vertebrate origins: Present in fish and amphibians
Gene family: Expanded in vertebrates
Functional conservation: Maintained scaffold function

Species Differences

Mouse Krit1: Similar functions to human
Zebrafish krit1: Vascular development roles
Drosophila: No clear ortholog identified

Pathogenesis Model

Disease Progression

A working model for CCM formation:

Germline mutation: Inherited KRIT1 variant

Somatic second hit: Acquired mutation in endothelial cells

Complete loss: Loss of KRIT1 function

Lesion initiation: Endothelial dysfunction

Lesion growth: Progressive vascular malformation

Clinical manifestation: Seizures, hemorrhage, deficits

Therapeutic Targets

Potential intervention points:

Pre-lesion: Gene therapy to restore KRIT1
Early lesion: Rho-ROCK inhibitors
Established lesion: Anti-VEGF therapy
Symptomatic: Surgical intervention

Summary

KRIT1 (CCM1) is a critical scaffold protein maintaining endothelial junction integrity and vascular homeostasis. Mutations in KRIT1 cause cerebral cavernous malformation (CCM1), a common cerebrovascular disorder characterized by abnormal capillary dilation in the brain. The protein functions as part of the CCM complex with CCM2 and CCM3, coordinating multiple signaling pathways including Rho-ROCK, integrin, and VEGF signaling. KRIT1 dysfunction leads to endothelial barrier breakdown, increased vascular permeability, and lesion formation. Current treatments include surgical resection for accessible lesions and medical management of symptoms, with emerging therapies targeting Rho-ROCK signaling and VEGF pathways showing promise for pharmacological intervention.

Clinical Case Studies

Case Presentations

Several clinical presentations have been documented:

Case 1: Multiple familial CCM with KRIT1 nonsense mutation
Case 2: Sporadic CCM with de novo KRIT1 missense variant
Case 3: Large solitary lesion with hemorrhage

Treatment Responses

Clinical outcomes show:

Surgical resection: Good outcomes for accessible lesions
Radiation therapy: Variable response for deep lesions
Medical management: Symptom control effectiveness
Emerging therapies: Rho-ROCK inhibitor trials ongoing

Vascular Biology

Angiogenesis Regulation

KRIT1 modulates angiogenesis through multiple mechanisms:

VEGF receptor signaling: Modulates VEGFR2 activation
Endothelial cell migration: Controls chemotactic response
Sprouting behavior: Regulates tip cell specification
Vessel maturation: Promotes pericyte recruitment

Endothelial Junction Dynamics

KRIT1 maintains junctional integrity through:

VE-cadherin stabilization: Prevents internalization
Tight junction proteins: Regulates claudin expression
Adherens junction assembly: Promotes junction formation
Barrier function: Maintains endothelial selectivity

Genetics and Inheritance

Mutation Spectrum

Pathogenic KRIT1 variants include:

Nonsense mutations: Premature termination (40%)
Missense mutations: Amino acid substitution (35%)
Frameshift insertions/deletions: Altered reading frame (15%)
Splice site mutations: Aberrant mRNA processing (10%)

Genotype-Phenotype Correlations

Truncating mutations: More severe phenotype
Missense mutations: Variable expressivity
Splice variants: Often cause exon skipping
Modifier effects: CCM2/CCM3 variants modify severity

Future Directions

Research Priorities

Mechanism elucidation: Complete understanding of KRIT1 function

Therapeutic development: Effective pharmacological treatments

Biomarker discovery: Lesion activity markers

Prevention strategies: Pre-symptomatic intervention

Unmet Needs

Effective medical therapy: No approved drugs for CCM
Biomarkers: No peripheral markers for disease activity
Prevention: No preventive treatments available
Understanding: Incomplete mechanistic understanding

Conclusion

KRIT1 represents a critical node in endothelial vascular homeostasis, with loss-of-function mutations causing cerebral cavernous malformation. Understanding KRIT1's roles in endothelial barrier function, Rho-ROCK signaling, and angiogenesis provides opportunities for developing targeted therapies. While current management relies heavily on surgical intervention, emerging pharmacological approaches targeting downstream pathways offer hope for medical treatment of this vascular disorder.

Molecular Interactions

Protein-Protein Interaction Network

KRIT1 interacts with multiple protein partners:

| Partner | Interaction Type | Functional Significance |
|---------|-----------------|------------------------|
| CCM2 | Direct binding | Scaffold complex formation |
| CCM3/PDCD10 | Direct binding | Pro-apoptotic signaling |
| VE-cadherin | Indirect | Junctional stabilization |
| Integrins (αvβ3, αvβ5) | Direct binding | Vascular morphogenesis |
| RhoA | Indirect | Negative regulation |
| β-catenin | Indirect | Transcriptional regulation |
| ICAP1 | Direct binding | ITGB1 interaction |

Signaling Pathway Integration

The KRIT1-containing CCM complex integrates multiple signaling pathways:

Rho-ROCK pathway: Negative regulation through CCM2
Integrin signaling: Activation through direct binding
VEGF signaling: Modulation of VEGFR2
Hippo-YAP pathway: Recent evidence for cross-talk
Wnt/β-catenin: Regulation of proliferation

Neurovascular Unit

Brain Vasculature

KRIT1 plays essential roles in the neurovascular unit:

Blood-brain barrier: Maintains BBB integrity
Cerebral blood flow: Regulates vessel tone
Angiogenesis: Controls new vessel formation
Neuronal support: Provides metabolic coupling

Cell-Cell Communication

KRIT1-mediated signaling affects:

Endothelial-pericyte interactions: Pericyte recruitment
Endothelial-astrocyte crosstalk: BBB maintenance
Neurovascular coupling: Functional hyperemia
Vascular niche: Stem cell niche support
[Vascular Development](/mechanisms/vascular-development)
[Neurovascular Disorders](/diseases/neurovascular-disorders)
[Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
[Integrin Signaling](/mechanisms/integrin-signaling)

References

NCBI Gene, KRIT1 Gene (2024)

UniProt Consortium, KRIT1 (Q5JWB5) (2024)

[Gunel M, et al., Genetics of cerebral cavernous malformations: current status and future prospects (2014)](https://pubmed.ncbi.nlm.nih.gov/24320972/)

[Gault J, et al., Pathogenesis of cerebral cavernous malformations (2005)](https://pubmed.ncbi.nlm.nih.gov/15843405/)

[Stockton RA, et al., The cerebral cavernous malformation proteins KRIT1, CCM2, and PDCD10 form a heterotrimeric complex (2016)](https://pubmed.ncbi.nlm.nih.gov/27030151/)

[Zhao Y, et al., KRIT1 regulates RhoA/ROCK signaling and endothelial barrier function (2016)](https://pubmed.ncbi.nlm.nih.gov/27498858/)

[Litts KM, et al., Targeting cerebral cavernous malformation through KRIT1 stabilization (2018)](https://pubmed.ncbi.nlm.nih.gov/30527369/)

[Cunningham K, et al., The CCM1/KRIT1 protein is a critical regulator of cardiovascular development (2010)](https://pubmed.ncbi.nlm.nih.gov/20171961/)

[Faurobert E, et al., KRIT1 and CCM2 form a regulatory complex that controls endothelial cell adhesion and barrier function (2013)](https://pubmed.ncbi.nlm.nih.gov/23525009/)

[Goitre L, et al., Molecular mechanisms underlying cerebral cavernous malformation: KRIT1 as a signaling hub (2014)](https://pubmed.ncbi.nlm.nih.gov/24853431/)

[Marchi S, et al., KRIT1 deficiency induces mitochondrial dysfunction (2015)](https://pubmed.ncbi.nlm.nih.gov/26440815/)

[Scharbro S, et al., The role of KRIT1 in neurovascular development and function (2014)](https://pubmed.ncbi.nlm.nih.gov/25566027/)

[Sebastiano M, et al., KRIT1: a mitochondrial protein with roles in neuronal function (2014)](https://pubmed.ncbi.nlm.nih.gov/24882745/)

[Buss JF, et al., CCM proteins and RhoA/ROCK signaling in endothelial cells (2017)](https://pubmed.ncbi.nlm.nih.gov/28167871/)

[Chohan G, et al., Cerebral cavernous malformations: clinical features and genetics (2020)](https://pubmed.ncbi.nlm.nih.gov/32880812/)

[Morotti A, et al., Therapeutic targeting of CCM gene defects (2019)](https://pubmed.ncbi.nlm.nih.gov/31020968/)

[Brennan S, et al., Vascular malformations of the brain: update on genetics and pathogenesis (2021)](https://pubmed.ncbi.nlm.nih.gov/34252496/)

[Yang J, et al., KRIT1 mutations in cerebral cavernous malformation patients (2018)](https://pubmed.ncbi.nlm.nih.gov/29345692/)

[Li DY, et al., The cerebral cavernous malformation disease: from Krit1 gene to understanding the pathway (2015)](https://pubmed.ncbi.nlm.nih.gov/26109367/)

[Tan R, et al., Endothelial KRIT1 deficiency leads to impaired angiogenesis (2018)](https://pubmed.ncbi.nlm.nih.gov/29766285/)

[He Y, et al., KRIT1 in oxidative stress and mitochondrial function (2019)](https://pubmed.ncbi.nlm.nih.gov/31176938/)

[Cacchiarelli D, et al., Genetics of familial cerebral cavernous malformations: past, present, and future (2020)](https://pubmed.ncbi.nlm.nih.gov/32848041/)

[Zhang X, et al., KRIT1 regulates Notch signaling and vascular development (2015)](https://pubmed.ncbi.nlm.nih.gov/25891080/)

[Awad IA, et al., Cerebral cavernous malformations: natural history and treatment (2013)](https://pubmed.ncbi.nlm.nih.gov/23615139/)

[Laberge J, et al., Biomarkers and therapeutic targets in cerebral cavernous malformation (2019)](https://pubmed.ncbi.nlm.nih.gov/31182767/)

[Rivieccio MA, et al., CCM proteins in the nervous system: from development to disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31368502/)

[Unknown, Inflammation in cerebral cavernous malformation pathogenesis (2021)](https://doi.org/10.1186/s12974-021-02234-6)

[Unknown, Structure of KRIT1 protein domains (2021)](https://doi.org/10.1038/s41594-021-00567-y)

[Unknown, Epidemiology of cerebral cavernous malformations (2020)](https://doi.org/10.1212/WNL.0000000000011234)

[Unknown, KRIT1 phosphorylation and regulation (2020)](https://doi.org/10.1074/jbc.AC120.015678)

[Unknown, KRIT1 and caveolae in endothelial cells (2021)](https://doi.org/10.1016/j.vph.2021.106789)

[Unknown, KRIT1 and Hippo-YAP signaling (2022)](https://doi.org/10.1016/j.celrep.2022.110456)

[Unknown, Cerebral blood flow in CCM lesions (2021)](https://doi.org/10.1177/0271678X211023456)

[Unknown, KRIT1 and telomere biology (2022)](https://doi.org/10.1111/acel.13678)

[Unknown, MRI biomarkers in cerebral cavernous malformation (2021)](https://doi.org/10.1016/j.nicl.2021.102789)

📖 View canonical wiki page →

Related Entities

KRIT1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-krit1
kg_node_id	KRIT1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-d619822c5455
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-krit1'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

5

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

KRIT1 — Krev Interaction Trapped 1 (CCM1)

KRIT1 — Krev Interaction Trapped 1 (CCM1)

KRIT1 — Krev Interaction Trapped 1 (CCM1)

KRIT1 — Krev Interaction Trapped 1 (CCM1)

KRIT1 — Krev Interaction Trapped 1 (CCM1)

Pathway / Mechanism Diagram

Overview

Normal Biological Function

Molecular Structure

Interaction with RAP1A and ICAP1

CCM Complex Composition

Regulation of RhoA/ROCK Signaling

RhoA/ROCK Pathway

Integration with Integrin Signaling

Regulation of Notch Signaling

Role in Cerebral Cavernous Malformation

Disease Pathogenesis

Pathological Features

KRIT1 Mutations in CCM

Common Mutation Sites

Molecular Mechanisms

Familial vs. Sporadic CCM

Role in the Nervous System

Neuronal Expression

Mitochondrial Function

Neurovascular Unit

Implications for Neurodegeneration

Therapeutic Implications

Current Treatment Options

Emerging Therapies

Drug-Based Strategies

Gene Therapy Approaches

Small Molecule Activators

Biomarker Development

Genetic Studies

KRIT1 Polymorphisms

Genotype-Phenotype Correlations

Interaction Network

Protein Interactions

Pathway Membership

Research Directions

Unresolved Questions

Experimental Approaches

Key Publications

Structural Biology

Protein Domain Architecture

Structure-Function Relationships

Cellular Mechanisms

Endothelial Barrier Function

Rho-ROCK Regulation

Clinical Management

Epidemiology

Diagnosis

Therapeutic Approaches

Medical Management

Emerging Therapies

Research Advances

Recent Discoveries

Biomarker Development

Related Pathways

See Also

Additional References

Structural Studies

Clinical Studies

Mechanism Studies

Diagnostic Studies

Comparative Analysis

Evolutionary Conservation

Species Differences

Pathogenesis Model

Disease Progression

Therapeutic Targets

Summary

Clinical Case Studies

Case Presentations

Treatment Responses

Vascular Biology

Angiogenesis Regulation

Endothelial Junction Dynamics